RA Efficacy, Safety Similar After Infliximab-to-SB2 Switch RA Efficacy, Safety Similar After Infliximab-to-SB2 Switch
Patients with RA who switched from infliximab to the biosimilar SB2 had ACR20 responses, adverse events, and immunogenicity profiles at 78 weeks similar to those in patients who continued infliximab.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Rheumatology News Source Type: news